Despite not being investigated here, the actuation parameters used with the SRDD device in the future could be modified in terms of pressure, ramp, and cycle number to trigger on‐demand and controlled insulin release to maintain blood glucose levels in the narrow normoglycemic range to prevent long‐term complications of hypo‐ or hyperglycemia.[88, 89] Hence, the SRDD system has the potential to be designed to treat an array of clinical conditions which require spatiotemporal drug delivery (Figure 5). The gene discussed is INS; the disease is Hyperglycemia.